Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR versus FC in previously untreated chronic lymphocytic leukemia
ISRCTN02757147Phase 3Completed
- Sponsor
- German CLL Study Group
- Start
- Jul 2003
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by German CLL Study Group. Primary endpoint: Progression-free survival. Started Jul 2003; status: completed.
02
Drugs
fludarabinecyclophosphamiderituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN02757147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN02757147.